|
|||||
|
|
B cell elimination in systemic lupus erythematosus |
|
| Authors: | João Furtado David A Isenberg |
| Institution: | 1. Department of Internal Medicine, Egas Moniz Hospital, Lisbon, Portugal;2. Centre for Rheumatology, Department of Medicine, University College London Hospital, London, UK |
| Abstract: | Systemic lupus erythematosus (SLE) is an autoimmune disorder with a worldwide distribution, potentially life-threatening with considerable morbidity. The elimination of pathogenic B cells has emerged as a rational therapeutic option. Many open label studies have reported encouraging results in which clinical and serological remission have invariably been described, often enabling the reduction of steroid and immunosuppressive treatment. However, the results from randomized controlled studies have been disappointing and several questions remain to be answered. In this review we will focus on results of B cell direct depletion in the treatment of patients with systemic lupus erythematosus. |
| Keywords: | ALMS Aspreva Lupus Management Study APRIL proliferation inducing ligand APS antiphospholipid syndrome BCDT B cell depletion therapy BILAG British Isles Lupus Assessment Group BLyS B lymphocyte stimulator protein ECLAM European Community Lupus Activity Measure EXPLORER Exploratory Phase II/III SLE Evaluation of Rituximab FDA Food and Drug Administration HACA host antibodies against the chimeric portion of rituximab ITP immune thrombocytopenia LN lupus nephritis LUMINA Lupus in Minorities: Nature vs Nurture LUNAR Lupus Nephritis Assessment With Rituximab PML progressive multifocal leukoencephalopathy SLAM Systemic Lupus Activity Measure SLE systemic lupus erythematosus SLEDAI Systemic Lupus Erythematosus Disease Activity Index TNF tumor necrosis factor |
| 本文献已被 ScienceDirect 等数据库收录！ | |